Enhancers mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer
暂无分享,去创建一个
S. Shousha | B. Győrffy | L. Magnani | G. Pruneri | A. Vingiani | P. Scacheri | G. Schiavon | D. Hadjiminas | C. Palmieri | G. Corleone | D. Patten | L. Pongor | Alina Saiakhova | R. Coombes | P. Barry | K. Goddard | Edina Erdős | Alina R. Saiakhova | Balázs Győrffy
[1] Richard A. Moore,et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy , 2017, Nature.
[2] Jennifer E. Phillips-Cremins,et al. YY1 and CTCF orchestrate a 3D chromatin looping switch during early neural lineage commitment , 2017, Genome research.
[3] P. Lønning,et al. Genomic Evolution of Breast Cancer Metastasis and Relapse , 2017, Cancer cell.
[4] G. Hager,et al. Single-molecule analysis of steroid receptor and cofactor action in living cells , 2017, Nature Communications.
[5] J. Vaquero,et al. Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance , 2017, Oncogene.
[6] G. Struhl,et al. Causal role for inheritance of H3K27me3 in maintaining the OFF state of a Drosophila HOX gene , 2017, Science.
[7] D. Moazed,et al. DNA sequence-dependent epigenetic inheritance of gene silencing and histone H3K9 methylation , 2017, Science.
[8] Jürg Müller,et al. Propagation of Polycomb-repressed chromatin requires sequence-specific recruitment to DNA , 2017, Science.
[9] James J. Morrow,et al. Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome , 2017, Nature Communications.
[10] A. Trumpp,et al. Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer , 2017, Nature Genetics.
[11] Mariella G. Filbin,et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma , 2016, Nature.
[12] N. Rosenfeld,et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.
[13] Martin A. Nowak,et al. Quantifying Clonal and Subclonal Passenger Mutations in Cancer Evolution , 2016, PLoS Comput. Biol..
[14] Marc J. Williams,et al. Identification of neutral tumor evolution across cancer types , 2016, Nature Genetics.
[15] B. L,et al. The accessible chromatin landscape of the human genome , 2016 .
[16] Dariusz M Plewczynski,et al. CTCF-Mediated Human 3D Genome Architecture Reveals Chromatin Topology for Transcription , 2015, Cell.
[17] Simak Ali,et al. Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis , 2017 .
[18] N. Hannett,et al. Transcription factor trapping by RNA in gene regulatory elements , 2015, Science.
[19] J. Forbes,et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.
[20] S. Loi,et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.
[21] Howard Y. Chang,et al. Single-cell chromatin accessibility reveals principles of regulatory variation , 2015, Nature.
[22] Rory Stark,et al. Progesterone receptor modulates estrogen receptor-α action in breast cancer , 2015, Nature.
[23] Andrew Menzies,et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing , 2015, Nature Medicine.
[24] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[25] Charles Y. Lin,et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. , 2015, Molecular cell.
[26] Michael Q. Zhang,et al. Integrative analysis of 111 reference human epigenomes , 2015, Nature.
[27] N. McGranahan,et al. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.
[28] Obi L. Griffith,et al. Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor , 2014, Nature.
[29] C. Caldas,et al. Progesterone receptor modulates ERa action in breast cancer , 2015 .
[30] Massimo Cristofanilli,et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.
[31] P. A. Futreal,et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.
[32] J. Carroll. Steroids, nuclear receptors and breast cancer. Preface. , 2014, Molecular and cellular endocrinology.
[33] Petra C. Schwalie,et al. Co-binding by YY1 identifies the transcriptionally active, highly conserved set of CTCF-bound regions in primate genomes , 2013, Genome Biology.
[34] Hanfei Sun,et al. Target analysis by integration of transcriptome and ChIP-seq data with BETA , 2013, Nature Protocols.
[35] M. Rots,et al. Towards Sustained Silencing of HER2/neu in Cancer By Epigenetic Editing , 2013, Molecular Cancer Research.
[36] A. Lánczky,et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer , 2013, Proceedings of the National Academy of Sciences.
[37] David A. Orlando,et al. Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.
[38] Mark Gerstein,et al. A comprehensive nuclear receptor network for breast cancer cells. , 2013, Cell reports.
[39] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[40] Data production leads,et al. An integrated encyclopedia of DNA elements in the human genome , 2012 .
[41] Shane J. Neph,et al. An expansive human regulatory lexicon encoded in transcription factor footprints , 2012, Nature.
[42] Nathan C. Sheffield,et al. The accessible chromatin landscape of the human genome , 2012, Nature.
[43] Swneke D. Bailey,et al. Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression , 2012, Nature Genetics.
[44] Alexey V. Gorshkov,et al. Quantum nonlinear optics with single photons enabled by strongly interacting atoms , 2012, Nature.
[45] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[46] ENCODEConsortium,et al. An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.
[47] J. Carroll,et al. Pioneer factors in hormone-dependent cancers , 2012, Nature Reviews Cancer.
[48] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[49] Eric S. Lander,et al. Chromatin modifying enzymes as modulators of reprogramming , 2012, Nature.
[50] C. Deng,et al. Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation , 2012, Oncogene.
[51] Tiziana Bonaldi,et al. Yin Yang 1 extends the Myc-related transcription factors network in embryonic stem cells , 2011, Nucleic acids research.
[52] I. Ellis,et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.
[53] J. Eeckhoute,et al. Pioneer factors: directing transcriptional regulators within the chromatin environment. , 2011, Trends in genetics : TIG.
[54] Jeannie T. Lee,et al. YY1 Tethers Xist RNA to the Inactive X Nucleation Center , 2011, Cell.
[55] Bin Wu,et al. Real-Time Observation of Transcription Initiation and Elongation on an Endogenous Yeast Gene , 2011, Science.
[56] Timothy J. Durham,et al. "Systematic" , 1966, Comput. J..
[57] Timothy J. Durham,et al. Systematic analysis of chromatin state dynamics in nine human cell types , 2011, Nature.
[58] Simak Ali,et al. Antiestrogens and their therapeutic applications in breast cancer and other diseases. , 2011, Annual review of medicine.
[59] J. Carroll,et al. FOXA1 is a critical determinant of Estrogen Receptor function and endocrine response , 2010, Nature Genetics.
[60] Cory Y. McLean,et al. GREAT improves functional interpretation of cis-regulatory regions , 2010, Nature Biotechnology.
[61] Z. Szallasi,et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.
[62] I. Ellis,et al. Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification , 2009, Breast Cancer Research.
[63] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[64] Michael D. Wilson,et al. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. , 2009, Methods.
[65] T. Sing,et al. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] Nathaniel D. Heintzman,et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression , 2009, Nature.
[67] Jiang Shou,et al. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. , 2008, Cancer research.
[68] R. Schiff,et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.
[69] M. Washburn,et al. YY1 functions with INO80 to activate transcription , 2007, Nature Structural &Molecular Biology.
[70] M. Donowitz,et al. Tissue-specific Regulation of Sodium/Proton Exchanger Isoform 3 Activity in Na+/H+ Exchanger Regulatory Factor 1 (NHERF1) Null Mice , 2007, Journal of Biological Chemistry.
[71] Nathaniel D. Heintzman,et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome , 2007, Nature Genetics.
[72] Malgorzata Schelder,et al. A Polycomb group protein complex with sequence-specific DNA-binding and selective methyl-lysine-binding activities. , 2006, Genes & development.
[73] Clifford A. Meyer,et al. Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.
[74] M. Ricote,et al. Interleukin-2 and its receptor complex (α, β and γ chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study , 2003, Breast Cancer Research.
[75] Robert H Singer,et al. Gene expression and the myth of the average cell. , 2003, Trends in cell biology.
[76] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[77] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] B Asselain,et al. Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. , 1998, Anticancer research.
[79] S. Colombatto,et al. Reduced IL-2 level concentration in patients with breast cancer as a possible risk factor for relapse. , 1996, European journal of gynaecological oncology.